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Hardy Mitdank , Meike Tröger , Alexander Sonntag ,
Nima Amini Shirazi , Eric Woith , Hendrik Fuchs , Dennis Kobelt ,




To appear in: European Journal of Pharmaceutical Sciences
Received date: 15 June 2021
Revised date: 13 December 2021
Accepted date: 21 December 2021
Please cite this article as: Hardy Mitdank , Meike Tröger , Alexander Sonntag , Nima Amini Shirazi ,
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Abstract 
Conventional eukaryotic expression plasmids contain a DNA backbone that is dispensable for 
the cellular expression of the transgene. In order to reduce the vector size, minicircle DNA 
technology was introduced. A drawback of the minicircle technology are considerable 
production costs. Nanoplasmids are a relatively new class of mini-DNA constructs that are of 
tremendous potential for pharmaceutical applications. In this study we have designed novel 
suicide nanoplasmid constructs coding for plant derived ribosome-inactivating proteins. The 
suicide-nanoplasmids were formulated with a targeted K16-lysine domain, analyzed for size, 
and characterized by electron microscopy. The anti-proliferative activity of the suicide-
nanoplasmids was investigated in vitro by real time microscopy and the expression kinetic 
was determined using an enhanced green fluorescent protein nanoplasmid variant. In an 
aggressive in vivo neuroblastoma tumor model, treated mice showed a reduced tumor growth 
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1. Introduction 
Conventional vectors (plasmids) contain genes for resistance factors that are necessary for the 
propagation in Escherichia coli. According to the European Medicines Agency (EMA), 
resistance genes should be avoided in the context of gene therapy (EMA, 2018), in order to 
exclude the transfer of an antibiotic resistance to the human microbial fauna. In addition, the 
bacterial backbone is being prone to induce an immune reaction since it is recognized as 
Pathogen Associated Molecular Pattern (PAMP). This effect is mediated by the activation of 
toll-like receptors (TLR9) (Klinman, 2004). With the introduction of minicircle technology 
(Kay et al., 2010) these factors were taken into account. Moreover, minicircle DNA is 
significantly smaller than the corresponding plasmid DNA, resulting in higher transfection 
efficacies (Hardee et al., 2017). However, a major drawback of this technology is the complex 
and cost-intensive production process starting with a parental plasmid from which the 
minicircle DNA is generated during propagation in genetically modified E. coli.  
An advanced development in the field was the invention of the nanoplasmid technology (Luke 
et al., 2009; Luke et al., 2014).  Nanoplasmids are small circular DNA constructs, which can 
be produced in large yields and without antibiotic resistance genes, while showing up to 10 
times higher transgene expression compared to minicircle vectors (Lu et al., 2017). Only few 
studies have been published, mainly dealing with the development of nanoplasmid DNA 
vaccine vectors (Chowdhury et al., 2020; Suschak et al., 2020). 
The concept of suicide vectors is based on the delivery of a DNA construct that encodes for a 
toxic factor (Navarro et al., 2016). Among the toxins the sequence of diphtheria toxin (DT) 
from Corynebacterium diphtheriae is one that is often used. DT targets the ribosomal protein 
machinery by ADP-ribosylation of elongation factor 2 (EF2) (Lin et al., 2015). Pseudomonas 
exotoxin A (PE) from Pseudomonas aeruginosa belongs to the same class of enzymes and 
acts identically via ADP-ribosylation of EF2. The DNA encoding PE has been used for the 
treatment of breast cancer stem cells (Moradian and Rahbarizadeh, 2019). The genetic 
information of further pore-forming toxins such as streptolysin O (SLO) from Streptococcus 
pyogenes (Yang et al., 2006) has been utilized, reviewed in (Pahle and Walther, 2016). A 
further class of toxins that have been investigated are type I ribosome-inactivating proteins 
(RIPs) from plants. Type I RIPs act as N-glycosylases (EC 3.2.2.22) and irreversibly 
inactivate protein synthesis by removing an essential adenine at position 4324 of the 
ribosomal rRNA (Endo, 1988). One advantage of type I RIPs for anti-tumoral applications is 
their high resistance against denaturation (Kokorin et al., 2019; Weise et al., 2020) and thus 
high stability. They show high enzymatic activity and in theory, one molecule of a RIP is 
sufficient to kill a cancer cell. It is therefore not surprising that RIPs have been used in suicide 
gene cancer studies (Sama et al., 2018a; Zarovni et al., 2009; Zarovni et al., 2007). However, 
in these studies conventional plasmid vectors were used to translocate the RIP genes into the 
nucleus of the target cells. To our knowledge, there are no published studies where a 
nanoplasmid vector was utilized for delivering a gene coding for a toxic factor.  
In this study we have designed two suicide nanoplasmid vectors. Nano-Sap encodes for  
saporin, which is a type I RIP from the plant Saponaria officinalis L. and well known in the 
context of cancer therapies (Polito et al., 2013). In vivo anti-cancer studies with saporin have 
         
been performed in the past (Falini et al., 1992). The second suicide nanoplasmid vector 
(Nano-Gyp) was constructed with the cDNA of a newly discovered type I RIP, gypsophilin-S 
from the organism Gypsophila elegans M. Bieb. (Kokorin et al., 2019). Both suicide 
nanoplasmid vectors were formulated with a receptor-targeted K16-lysine domain. In vitro 
studies were performed using neuroblastoma cells and the in vivo efficiency was investigated 
in a corresponding tumor model with tumor bearing nu/nu NMRI mice. To increase the 
transfection efficacy of the complexed suicide nanoplasmid vectors, a transfection enhancer 
that we have recently identified in the organism Agrostemma githago L. was applied as well 
(Clochard et al., 2020). 
2. Materials and methods 
2.1 Construction of suicide nanoplasmids 
Starting with the amino acid sequence of gypsophilin-S (Gyp) – a type I ribosome-
inactivating protein from Gypsophila elegans M. Bieb. (Kokorin et al., 2019) – the cDNA was 
generated by gene synthesis and integrated in a mammalian gene expression plasmid vector 
(VectorBuilder, Neu-Isenburg, Germany). Subsequently, the gene of Gyp was flanked by 
cleavage sites for SalI/NheI via polymerase chain reaction (PCR). The resulting insert was 
isolated via agarose gel electrophoresis, extracted from the band cutout, and simply integrated 
by blunt end ligation into the pJET1.2 cloning vector (CloneJET PCR cloning kit, Thermo 
Fisher, Waltham, USA). This step enables propagation of plasmid DNA in E. coli in order to 
have sufficient amounts for restriction, extraction from agarose gel and ligation (briefly for 
the cloning into the destination vector). The gene of saporin (Sap) was taken from a pET11d 
bacterial expression vector and cloned into the pJET1.2 vector in the same manner. The 
resulting pJET1.2 plasmids were originally used for other purposes but coincidentally bear 
suitable cleavage sites (SalI/XbaI) for cloning the genes of interest into the nanoplasmid 
vector of Nature Technology Corporation (NTC).  
The nanoplasmids NTC9385R-Gyp-BGH pA (2573 bp) and NTC9385R-Sap-BGH pA (2585 
bp) as well as NTC9385R-EGFP-BGH pA (2487 bp), the corresponding nanoplasmid 
encoding for enhanced green fluorescent protein (eGFP), were produced by Nature 
Technology Corporation, Lincoln, USA. The transgenes were under control of a chimeric 
promotor consisting of CMV HTLV-I.  
The functionality and the production process of nanoplasmids was summarized in a poster by 
(Aaron Carnes, 2016). In summary, the nanoplasmid construct has a size-reduced origin of 
replication (300 bp instead of 1000 bp) and works with RNA-OUT antibiotic-free selection. 
Special host strains are necessary for the nanoplasmid production. Successfully transformed 
bacteria are selected with sucrose instead of antibiotics, based on the accumulation of the 
polysaccharide levan in the periplasm, which is toxic to E. coli. Levan consists of fructose 
monomers and a terminal glucose and is formed by levansucrase while degrading the sucrose. 
Levansucrase is chromosomally coded in the host strain. Consequently, untransformed 
bacteria die, while bacteria carrying the nanoplasmid survive due to hybridization of the 
levansucrase coding mRNA (gene silencing). Furthermore, NTC has optimized the 
fermentation process and combined it with a patented lysis process to obtain remarkable 
         
yields. After a period of time with high biomass production and low plasmid amplification at 
lower temperature (30°C), the temperature is elevated to 42 °C, which induce the expression 
of high copy replication proteins and therefore increase the plasmid propagation 
tremendously. Good manufacturing practice conform production is possible. 
2.2 Isolation and characterization of transfection enhancer 
The transfection enhancer agrostemmoside E (AG1856) was isolated from Agrostemma 
githago L. by a combination of size-exclusion chromatography and HPLC (Clochard et al., 
2020). AG1856 was characterized by LC-MS (LC-MS-Triple Quadrupole 6400, Agilent 
Technologies®, Palo Alto, CA, USA). The structure of AG1856 was presented previously 
and is described elsewhere (Clochard et al., 2020). The transfection enhancer AG1856 
exhibits excellent water solubility. The transfection process is improved by modulating the 
endosomal escape process of internalized nanoplexes (Weng et al., 2015). For all in vitro and 
in vivo experiments AG1856 was applied separately. It was not formulated into the 
nanoplexes.  
2.3 Formulation of nanoplasmids 
The receptor-targeted peptide (Sama et al., 2018a) (Weng et al., 2015) (Tagalakis et al., 2011) 
(Hart et al., 1998) with the amino acid sequence K(16)GACYGLPHKFCG (peptide Y) was 
produced by GeneCust (Boynes, France). In previous studies it was shown that the integrin 
like sequence GACYGLPHKFCG facilitates the efficient transfection of nanoplexes 
(Tagalakis et al., 2011). Nanoplexes were formulated by admixing same volumes of peptide Y 
and DNA solution in ultrapure water, followed by a 30-minute incubation period at room 
temperature. Due to the 16-fold lysine domain peptide Y is positively charged and the primary 
amino groups of the lysines are protonated at neutral pH-value. Due to the backbone 
containing each one phosphate groups per nucleotide, DNA is a poly-anionic molecule. 
Because of the electrostatic interaction a nano-suspension will be obtained following the 
mixing of peptide Y with DNA.  
Sap- and Gyp-nanoplexes for in vitro experiments were formulated at a mass ratio of 7:1 
(peptide: DNA) whereas a mass ratio of 4:1 was used for eGFP- and Sap-nanoplexes for the 
in vivo experiments. N/P ratios, defined as the molar ratio of positively charged amino groups 
in the peptide to negatively charged nucleic acid phosphate groups, were calculated to be 11.7 
(for mass ratio 7:1) and 6.4 (for mass ratio 4:1), respectively.    
2.4 Characterization of nanoplexes 
The morphology of the targeted suicide nanoplexes was investigated by scanning electron 
microscopy (SEM) using a Hitachi SU 8030 scanning electron microscope (Hitachi, Tokyo, 
Japan) at 15 kV. The samples (5 µL) for SEM were taken from formulations that were 
produced as for the animal experiments. The sample was dried overnight on silicon waver at 
RT prior measurement. 
The DNA complexation was analysed by agarose gel electrophoresis (Sama et al., 2017). 
Nanoplexes with 500 ng nanoplasmid per approach were formulated with peptide Y in a total 
volume of 30 μL as described above. Equivalent amounts of free nanoplasmid as control and 
         
the nanoplexes were electrophoresed on a 1% agarose gel, stained with ethidium bromide, and 
visualized under UV. 
The hydrodynamic diameter (DH) and the ζ-potential of all nanoplexes used within this study 
were measured by dynamic light scattering (DLS) and laser Doppler micro-electrophoresis 
using a Malvern Zetasizer Nano ZS instrument (Malvern Instruments, Worcestershire, United 
Kingdom), equipped with a 4 mV HeNe laser, 633 nm, at a fixed scattering angle of 173°. For 
each nanoplex, 2.5 μg DNA were complexed in a total volume of 50 μL as described above. 
The nanoplex solution was incubated at room temperature for 30 minutes and transferred into 
a disposable UV-transparent micro cuvette for size measurements. Cumulants analysis, as 
defined in ISO 13321:1996 and ISO 22412:2017, was used for the analysis of the 
autocorrelation functions by the Zetasizer software, producing a mean value for the DH (Z-
Average) and a width parameter of the monomodal curve known as polydispersity index 
(PdI). Size distributions were obtained by the Zetasizer software using the CONTIN algorithm 
to fit the correlation function to the optimal number of exponentials. For ζ-potential 
measurements, the nanoplex solution was diluted with ultrapure water to a final volume of 
800 μL and supplemented with NaCl to a final concentration of 10 mM before transferring the 
complete solution to a folded capillary cell. Each measurement was performed three times 
with a minimum number of 10 sub-runs per measurement.  
2.5 Cell culture and live cell imaging 
Murine neuroblastoma cells Neuro2A (ATCC® CCL-131™) and Neuro2A cells that were 
stable transfected with the luciferase gene (Sama et al., 2018b) (Neuro2A_Luc) were 
cultivated in BioWhittaker® Dulbecco´s Modified Eagle´s Medium (DMEM) (Lonza Group, 
Basel, Switzerland) supplemented with 10 % FBS and non-essential amino acids (Lonza 
Group, Basel, Switzerland) in a 5 % CO2 atmosphere and 37 °C. For in vitro transfections 
cells were seeded in clear well-plates and cultivated for 24 h. After this, the culture medium 
was exchanged with a mixture of freshly formulated nanoplexes (described above), culture 
medium (described above) and AG1856 (final concentration: 5 µg/ mL). Cells (4000 per well) 
were seeded in 96-well-plates and 100 ng DNA was formulated per well for in vitro 
transfections with suicide nanoplexes, the total culture volume per well was 200 µL. After the 
transfection, the cells were observed for 48 h. The cytotoxic effect was measured by a 
CytoSMART® Omni live cell imaging device (CytoSMART Technologies, Eindhoven, the 
Netherlands). Cell growth was monitored for 72 h. For in vitro transfections with eGFP-
nanoplexes (500 ng per well), 15 000 cells per well were seeded in 24-well-plates in a culture 
volume of 400 µL. A CytoSMART® Lux3 FL, a small fluorescence live-cell imaging 
microscope, was used to monitor cell growth and eGFP expression during the 48-hour 
incubation period. The transfection efficiency was determined using flow cytometry. All cells 
exhibiting higher FITC-H signals than the untreated control cell population, were considered 
as transfected.  
2.6 In vivo studies, toxicity, efficacy, and luciferase imaging 
All animal studies were conducted in compliance with the United Kingdom Coordinated 
Committee on Cancer Research guidelines and have been authorized by the Landesamt für 
         
Gesundheit und Soziales, Berlin, Germany. All the studies were performed with Rj:NMRI-
Foxn1
nu/nu
 (NMRI-nu/nu) mice, obtained by Janvier Labs. To assess acute toxicity, two mice 
received 90 µg AG1856 (50 µL) subcutaneously. One hour later 100 µL nanoplex 
formulations (NP) were applied intravenously in the tail vein (30 µg DNA/ mouse). This was 
repeated on day 3 and 6. Mice were observed and the body weight was measured regularly. In 
order to perform the chronic toxicity study, the same mice received applications of 90 µg 
AG1856 (50 µL) subcutaneously and one hour later 100 µL NP on day 27, 31, 34 and 36. The 
mice were observed regularly and body weight was recorded until study termination on day 
48. For the anti-tumoral effect, efficacy was investigated in the Neuro2A xenograft model. 
Neuro2A cells that have been stably transduced with the luciferase gene (Sama et al., 2018a) 
were injected subcutaneously in the left flank (10
7 
cells per inoculation) in NMRI-nu/nu mice 
(6 – 8 weeks old). Then, mice were randomized to 8 mice/ group (in total 3 groups). The 
suicide gene therapy was started one day after the inoculation and was repeated on day 3, 5, 7 
and 9. The application scheme and the study design was based on previous studies (Sama et 
al., 2018a). The tumor growth was determined by calliper measurements. The application 
scheme was as described above. One group received placebo (PBS), one group only targeted 
suicide NP (30 µg DNA) and the third group NP (30 µg DNA) + AG18156 (90 µg). From 
study day 11 on, bioluminescence imaging was performed by using the NightOWL LB 981 
imaging system (Berthold Technologies, Bad Wildbad, Germany) as described elsewhere 
(Sama et al., 2018a). 
3. Results and discussion 
3.1 Targeted suicide nanoplexes   
The morphology of the Sap-NP (4:1) that were used for the in vivo study, were analysed using 
scanning electron microscopy (SEM) (Fig. 1). The analysis revealed rod like structures with a 
width of roughly 50 nm and a length of roughly 200 nm. This is an interesting observation 
because it was shown that the shape of a nanoparticle has an impact on the biological effect, 
e.g. rode like structures exhibited higher anti-cancer activity than spherical particles (Scarpa 
et al., 2020). It is obvious that the shape might modulate the endocytosis of the nanoplex into 
a cell (Zhang et al., 2015).  
Fig. 1. SEM-images of targeted suicide nanoplexes (Sap-NP). Analysis revealed rod like structures. 
 




3.2 Sizing and gel retention assay 
The complexation of the DNA was assessed by agarose gel electrophoresis of the formulated 
nanoplexes. As shown in Fig. 2, no free DNA was detected in the nanoplex formulations, 
indicating complete complexation. 
 
Fig. 2 Agarose gel retention analysis of formulated nanoplexes. Lane 1: DNA Ladder labeled with corresponding number of 
kilobases, lane 2: eGFP-Nanoplasmid, lane 3:  eGFP-Nanoplex (4:1), lane 4: Gyp-Nanoplasmid, lane 5: Gyp-Nanoplex (7:1), 
lane 6: Sap-Nanoplasmid, lane 7: Sap-Nanoplex (4:1), lane 8: Sap-Nanoplex (7:1). In all lanes with formulated nanoplexes 
(3, 5, 7, and 8) no free DNA was detected, showing complete complexation of the used nanoplasmids by the targeted peptide. 
 
Nanoplexes were characterized regarding their size, PdI and ζ-potential by DLS and laser 
Doppler micro-electrophoresis. All measured nanoplex formulations resulted in the formation 
of cationic nanoparticles with positive ζ-potential (table 1). The nanoplexes show a relatively 
narrow particle size distribution (PdI < 0.3) with mean hydrodynamic diameters between 45 
and 61 nm (Fig. 3, table 1). 
         
 
Fig. 3 Size Distribution of formulated nanoplexes. The different colors represent individual measurements of the same 
sample. All measured nanoplexes exhibit a relatively narrow size distribution with average hydrodynamic diameters < 100 
nm. In the case of Sap- and Gyp-nanoplexes, a minor share with diameters ˃ 1 μm is observed, probably due to aggregate 
formation.  
Table 1: Hydrodynamic diameter (DH), polydispersity index (PdI) and ζ-potential of formulated nanoplexes. Samples were 
measured in triplicate after 30 min incubation at room temperature, mean value ± standard deviation is reported. All tested 
formulations gave rise to cationic nanoparticles, with ζ-potentials between + 29 and + 37 mV and DH between 46 and 61 nm, 
PdIs < 0.3.  
 DH [nm] PdI ζ-Potential [mV] 
eGFP-Nanoplex (4:1) 57.34 ± 0.2 0.14 ± 0.01 29.4 ± 3 
Sap-Nanoplex (4:1) 60.88 ± 4 0.27 ± 0.02 33.2 ± 2 
Sap-Nanoplex (7:1) 46.46 ± 2 0.22 ± 0.03 31.2 ± 3 
Gyp-Nanoplex (7:1) 53.01 ± 0.7 0.221 ± 0.003 36.6 ± 1 
 
3.3 Transfection efficacy of nanoplasmids  
The transfection efficacy of the nanoplasmids was determined using an eGFP nanoplasmid 
construct formulated with peptide Y ± AG1856 and lipofectamine as positive control. As 
depicted in Fig. 4, nanoplexes alone carrying the eGFP-gene showed very low transfection 
efficacy whereas the combination with the transfection enhancer AG1856 caused a booster of 
the transfection efficacy to ~ 80 %. This value was far above the level of lipofectamine, which 
































































Size Distribution by Intensity, eGFP-Nanoplex (4:1)
         
 
Fig. 4 Transfection efficacy of eGFP-nanoplasmids. Neuro2A cells were transfected with eGFP-nanoplasmids using peptide 
Y ± AG1856 (5 µg/ mL) and lipofectamine. After 48 h cells were analyzed by fluorescence microscopy (upper panel) and 
flow cytometry (lower panel). Upper panel, from left to right: Control cells, eGFP-nanoplasmid/ lipofectamine, eGFP-
nanoplasmid/ peptide Y (NP), eGFP-nanoplasmid-peptide Y/AG1856 (NP + AG1856). Lower panel: Transfection efficacy. 
The formulation NP (nanoplasmid/ peptide Y) + AG1856 (5 µg/mL) showed the highest transfection efficacy. Results are 
expressed as mean ± SD, n=3. Two-sided t-test, ****p ≤ 0.0001.   
The eGFP expression profile was investigated in Neuro2A cells in a live cell imaging 
experiment over 48 h. The expression of eGFP started already 6 h after transfection. 
Compared to regular plasmid-DNA the nanoplasmids are reduced in size, which may 
contribute to a faster delivery into the nucleus. It was shown that the transfection efficiency 
depends on the size of the DNA-vector (Hornstein et al., 2016). The whole video sequence 
from which Fig. 5 was generated can be found in the supplementary information (videoS1). 
 
Fig. 5 Kinetics of eGFP expression in Neuro2A cells after transfection with eGFP-nanoplexes, supplemented with 5 µg/mL 
AG1856. Cell coverage in percent in both the brightfield and the green (excitation: 452 ± 45 nm) channel were determined by 
the CytoSMART® Cloud Service by means of image analysis. Fluorescent coverage ratio is determined by Cell coverage 
Green Fluorescence [%]/ Cell coverage Brightfield [%] * 100 % and is indicating the share of eGFP-expressing cells. The 
expression of eGFP started 6 h after transfection and the proportion of eGFP-expressing cells constantly increased during the 
48-hour incubation period.   
 
         
3.4 In vitro efficacy of targeted suicide nanoplexes 
After we had observed the delivery efficacy of the eGFP-nanoplexes in combination with 
AG1856, we aimed to transfer these promising results to a rather more therapeutically 
relevant scenario. For this reason, we designed suicide nanoplasmids by ligating the cDNAs 
of the ribosome-inactivating proteins saporin from Saponaria officinalis L. and gypsophilin-S 
from Gypsophila elegans M. Bieb. into the nanoplasmids. By the formulation with peptide Y, 
targeted suicide nanoplexes were generated. Cells that were only treated with targeted suicide 
nanoplexes but not with AG1856 showed no sign of an inhibition of proliferation. However, 
the proliferation of cells that were treated with targeted suicide nanoplexes + AG1856 was 
strongly inhibited shortly (~12 h) after addition of the compounds (Fig. 6) This was due to an 
expression of the ribosome-inactivating proteins saporin and gypsophilin-S and thus an 
irreversible inhibition of protein synthesis.  
 
Fig. 6 Live cell imaging (CytoSMART® Omni) of the efficacy of targeted suicide nanoplexes in neuroblastoma cells. 
Neuro2A and Neuro2A_Luc cells were treated with targeted nanoplexes ± AG1856. Cells treated with both components 
showed strong inhibition of cell proliferation. Cell proliferation was normalized to the point of intervention (addition of 
compounds, t = 24 h). Both groups showed a significantly reduced growth in comparison to the negative control and the 
AG1856-free groups (U-Test, p<0.05).  
The results obtained from the in vitro experiments with the targeted suicide nanoplasmids 
confirmed the results from the experiments with eGFP-nanoplasmids and showed the 
excellent efficacy of the transfection enhancer AG1856. In the next step, we attempted to 
translate these results into in vivo conditions. It was envisaged to investigate the anti-tumoral 
efficacy of the targeted suicide nanoplexes in a neuroblastoma animal model using Neuro2A 
         
cells that were transduced with the luciferase gene. In advance to the therapy study, an in vivo 
toxicity study was performed. 
3.5 In vivo toxicity studies 
The toxicity of the gene therapy was investigated in NMRI-nu/nu mice. The transfection 
enhancer AG1856 was applied subcutaneously into the neck fold and one hour later, the 
targeted suicide nanoplasmids were injected into the tail vein. As depicted in Fig. 7, mice 
tolerated the therapy very well. No decrease of bodyweight was observed, and no signs of any 
other irritations were noted.  
 
Fig. 7 Toxicity study of targeted suicide nanoplexes and AG1856. Two NMRI nu/nu mice received in total 6 applications of 
AG1856 (s.c.) and targeted suicide nanoplexes (i.v.). The body weight was determined regularly. No reduction of body 
weight was observed, and mice behaved normally. 
3.6 In vivo anti-tumoral efficacy study 
Next, we investigated the anti-tumoral efficacy of the targeted suicide nanoplexes (TN) in 
vivo. Based on our relevant experimental experience with Sap-plasmids (Sama et al., 2018a) 
and Sap-protein (Weng et al., 2012) we decided to use the Nano-Sap construct for the efficacy 
study. It should be noted that the selected tumor model is a very aggressive tumor model and 
tumors are growing with great speed. Against this background we obtained promising results 
showing a considerable decrease of tumor growth by the targeted suicide compared to mock 
treated mice (see Fig. 8). Investigation of liver enzyme activity in the serum did not show any 
significant differences between all groups indicating a well-tolerated treatment. In TN/ 
AG1856-treated mice an outlier, which was included in the statistical evaluation, was 
observed with a very big tumor. The data was statistically analysed by one-way-ANOVA, but 
significant differences were not detected. However, the median of TN/ AG1856-treated mice 
was still lower than the median of TN treated mice.  




Fig. 8 (A) Box-plot diagram of anti-tumoral efficacy of targeted suicide nanoplexes (TN) in tumor bearing mice. Mice 
(NMRI nu/nu, 8/ group) obtained either PBS (mock) or TN (i.v.) with or without AG1856 (s.c.). Mice treated with TN ± 
AG1856 showed a slower tumor growth than mock mice. (B) Luciferase imaging of tumors applying luciferin (150 mg/kg) 




         
4. Discussion 
In this study we have constructed targeted suicide nanoplexes. Our aim was to provide 
evidence whether such nanoplexes are suitable for anti-tumor treatment in vivo. It should be 
noted that this is the first study presenting suicide vectors based on nanoplasmids. The suicide 
nanoplexes were formulated by simple pipetting with targeted lysine peptide. The resulting 
morphology is intriguing since rod like nanoparticles were generated. A normal plasmid 
construct (~ 5000 bp) with the same suicide gene (saporin) formulated with the same targeting 
peptide as we used in this study resulted in the formation of normal spheres (Sama et al., 
2018a). This is an interesting observation since it is known that the morphology does 
modulate the endocytosis (Zhang et al., 2015) and the membrane wrapping (Tang et al., 2018) 
of nanoparticles. The morphology is therefore an important factor for the transfection efficacy 
since endocytosis is the first prerequisite for a successful delivery. However, it is also obvious 
that an excellent endocytosis does not necessarily go hand in hand with an excellent 
transfection efficiency. What is necessary is the ability to escape from endosomes/ lysosomes 
inside the cell (Smith et al., 2019). We have recently identified a natural product (AG1856) 
from the plant Agrostemma githago L. (Clochard et al., 2020). It is composed of a 
hydrophobic triterpene backbone and two complex carbohydrate chains attached to this 
backbone. As shown in this study AG1856 greatly improved the transfection efficiency of the 
targeted suicide nanoplexes in Neuro2A cells in vitro. We have already shown that 
compounds such as AG1856 improve the endosomal escape process of gene-nanoplexes 
(Weng et al., 2015). However, a superiority of AG1856 is the extremely low self-toxicity 
(Clochard et al., 2020). This is confirmed by the in vivo toxicity results presented in this 
study. Here, we injected a high dose of 90 µg AG1856 per mice. Assuming a maximal blood 
volume of 1.5 mL and that all AG1856 is distributed in the blood stream, this corresponds to a 
theoretical concentration of 60 µg/ mL. This shows that AG1856 also exhibits a very good 
tolerance in vivo. In this study, AG1856 tremendously enhanced the transfection efficacy of 
eGFP- as well as of suicide nanoplasmids. In the in vivo experiments, this strong enhancement 
was not observed, which could be due to an inefficient transport of the nanoplexes to the 
tumor and a deficient penetration through the tumor tissue. Considering the fenestration of 
tumor vasculature an optimized formulation method, producing nanoplexes with optimized 
size and low polydispersity index could contribute to a better penetration (Tang et al., 2014). 
In principle it might be assumed that the suicide nanoplexes also affect other cells than tumor 
cells. As shown in this study no toxicity was observed in healthy cells, which might be due to 
the targeting effect, mediated by peptide y that was used for the formulation of the 
nanoplexes. Another explanation might be the much higher metabolic activity paralleled by a 
higher protein synthesis rate and transcription rate of fast growing tumor cells. It can be thus 
assumed that the neuroblastoma cells transcribe and translate the suicide genes much more 
efficient compared to slowly growing healthy cells. 
Another important factor that needs to be investigated in future studies is an optimized 
application scheme for AG1856. In this study we followed an application scheme applying 
the compound s.c. (Sama et al., 2018a). Other applications need to be investigated in terms of 
an optimal flow into the tumor. A straightforward way would be an i.v. application together 
         
with the nanoplexes. To identify the perfect application scheme is therefore a balancing 
between unspecific toxicity and anti-tumoral efficacy. 
4. Conclusion 
In this study we have shown, that targeted suicide nanoplexes harboring novel nanoplasmids 
show high activity in vitro in neuroblastoma cells. We translated these in vitro results into an 
in vivo model. The suicide nanoplasmid formulations showed an anti-tumoral activity, 
however compared to the in vitro results the anti-tumoral efficacy was moderate. The efficacy 
of the nanoplexes might be improved by optimizing the formulation protocols, resulting in a 
reduced size variation and subsequent improved delivery of the nanoplexes to the tumor site.  
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